Procaps Group Ownership
| PROC Stock | USD 1.47 0.72 96.00% |
Procaps |
Procaps Stock Ownership Analysis
About 83.0% of the company outstanding shares are owned by corporate insiders. The book value of Procaps Group was at this time reported as 0.39. The company had not issued any dividends in recent years. Procaps Group SA had 1:1 split on the 30th of September 2021. Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company was founded in 1977 and is based in Luxembourg, Luxembourg. Procaps Group is traded on NASDAQ Exchange in the United States. To find out more about Procaps Group SA contact the company at 356 7995 6138 or learn more at https://www.procapsgroup.com.Besides selling stocks to institutional investors, Procaps Group also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Procaps Group's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Procaps Group's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Procaps Group Quarterly Liabilities And Stockholders Equity |
|
About 83.0% of Procaps Group SA are currently held by insiders. Unlike Procaps Group's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Procaps Group's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Procaps Group's insider trades
Procaps Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Procaps Group is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Procaps Group SA backward and forwards among themselves. Procaps Group's institutional investor refers to the entity that pools money to purchase Procaps Group's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Itau Unibanco Holding Sa | 2024-12-31 | 178 K | Geode Capital Management, Llc | 2024-12-31 | 33.3 K | Activest Wealth Management | 2024-12-31 | 10 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 100.0 | Ubs Group Ag | 2024-12-31 | 49.0 | State Street Corp | 2024-09-30 | 0.0 | Exome Asset Management Llc | 2024-12-31 | 0.0 | Royal Bank Of Canada | 2024-09-30 | 0.0 | Pineridge Advisors Llc | 2024-12-31 | 0.0 |
Procaps Group Outstanding Bonds
Procaps Group issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Procaps Group SA uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Procaps bonds can be classified according to their maturity, which is the date when Procaps Group SA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Procaps Group SA offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Procaps Group's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Procaps Group Sa Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Procaps Group Sa Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Procaps Group SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Procaps Group. If investors know Procaps will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Procaps Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.64) | Earnings Share 0.66 | Revenue Per Share | Quarterly Revenue Growth 0.073 | Return On Assets |
The market value of Procaps Group SA is measured differently than its book value, which is the value of Procaps that is recorded on the company's balance sheet. Investors also form their own opinion of Procaps Group's value that differs from its market value or its book value, called intrinsic value, which is Procaps Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Procaps Group's market value can be influenced by many factors that don't directly affect Procaps Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Procaps Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Procaps Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Procaps Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.